Shree Ganesh Remedies
Q2 revenue ₹23.29 Cr, up 62% QoQ but down 23% YoY; EBITDA margin fell to 17% from 32%. Management's 'stronger performance ahead' has no numbers, and it admits the recovery is incomplete.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Shree Ganesh Remedies earnings call we streamed: the live audio and our summary of what management said.
Q2 revenue ₹23.29 Cr, up 62% QoQ but down 23% YoY; EBITDA margin fell to 17% from 32%. Management's 'stronger performance ahead' has no numbers, and it admits the recovery is incomplete.
Q2 revenue ₹23.29 Cr, up 62% QoQ but down 23% YoY; EBITDA margin fell to 17% from 32%. Management's 'stronger performance ahead' has no numbers, and it admits the recovery is incomplete.
No revenue or margin guidance given. Commercial supply from Q1 FY28; ~80% plant utilisation at peak, in three years.
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.